Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer

Phase 1

Completed

Conditions: Locally Recurrent and Metastatic Breast Cancer

Interventions: Drug: Docetaxel
Drug: Paclitaxel
Drug: AMG 706

First Posted Date: 2006-05-05

Last Posted Date: 2013-07-31

Lead Sponsor: Amgen

Target Recruit Count: 46

Registration Number: NCT00322400

A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: paclitaxel
Drug: gemcitabine
Drug: bevacizumab

First Posted Date: 2006-05-03

Last Posted Date: 2013-07-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 187

Registration Number: NCT00320541

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico

A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Bevacizumab
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2006-04-26

Last Posted Date: 2010-05-11

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 47

Registration Number: NCT00318136

A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer

Phase 2

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Paclitaxel
Drug: Bevacizumab

First Posted Date: 2006-04-24

Last Posted Date: 2011-05-02

Lead Sponsor: Hoosier Cancer Research Network

Target Recruit Count: 34

Registration Number: NCT00317200

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
🇺🇸
Cancer Care Center of Southern Indiana, Bloomington, Indiana, United States

and more 14 locations

Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: gemcitabine
Drug: paclitaxel

First Posted Date: 2006-04-20

Last Posted Date: 2009-06-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT00316199

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China

Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients

Phase 1

Completed

Conditions: Stage IV Breast Cancer
Ovarian Epithelial Cancer Stage III
Stage IV Ovarian Cancer

First Posted Date: 2006-04-20

Last Posted Date: 2011-02-18

Lead Sponsor: Swedish Medical Center

Target Recruit Count: 30

Registration Number: NCT00316407

Locations: 🇺🇸
Swedish Medical Center Cancer Institute, Seattle, Washington, United States
🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Epithelial Ovarian Cancer
Primary Peritoneal Cancer

First Posted Date: 2006-04-14

Last Posted Date: 2016-12-08

Lead Sponsor: John P. Fruehauf

Target Recruit Count: 40

Registration Number: NCT00314678

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Lung Cancer
Esophageal Cancer
Extragonadal Germ Cell Tumor
Bladder Cancer
Ovarian Cancer
Prostate Cancer
Brain and Central Nervous System Tumors
Breast Cancer
Gastric Cancer

Interventions: Drug: lapatinib
Drug: paclitaxel

First Posted Date: 2006-04-12

Last Posted Date: 2014-07-02

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 28

Registration Number: NCT00313599

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2006-04-06

Last Posted Date: 2013-06-26

Lead Sponsor: Gruppo Italiano Mammella (GIM)

Target Recruit Count: 280

Registration Number: NCT00311636

Locations: 🇮🇹
Ospedale Civile, Castelfranco - TV, Italy
🇮🇹
Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
🇮🇹
Ospedale Sant Anna, Como, Italy

and more 15 locations

Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium

Phase 2

Completed

Conditions: Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter

First Posted Date: 2006-04-03

Last Posted Date: 2018-08-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 71

Registration Number: NCT00310011

Locations: 🇺🇸
Carolinas Hematology-Oncology Associates, Charlotte, North Carolina, United States
🇺🇸
Regional Cancer Center, Greensboro, North Carolina, United States
🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy